| Drug Name |
Clomipramine hydrochloride |
| Drug ID |
BADD_D00500 |
| Description |
Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, clomipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as clomipramine, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H1 receptors, α1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Clomipramine may be used to treat obsessive-compulsive disorder and disorders with an obsessive-compulsive component (e.g. depression, schizophrenia, Tourette’s disorder). Unlabeled indications include panic disorder, chronic pain (e.g. central pain, idiopathic pain disorder, tension headache, diabetic peripheral neuropathy, neuropathic pain), cataplexy and associated narcolepsy, autistic disorder, trichotillomania, onchophagia, stuttering, premature ejaculation, and premenstrual syndrome. Clomipramine is rapidly absorbed from the gastrointestinal tract and demethylated in the liver to its primary active metabolite, desmethylclomipramine. |
| Indications and Usage |
May be used to treat obsessive-compulsive disorder and disorders with an obsessive-compulsive component (e.g. depression, schizophrenia, Tourette’s disorder).
Unlabeled indications include: depression, panic disorder, chronic pain (e.g. central pain, idiopathic pain disorder, tension headache, diabetic peripheral neuropathy, neuropathic pain), cataplexy and associated narcolepsy (limited evidence), autistic disorder (limited evidence), trichotillomania (limited evidence), onchophagia (limited evidence), stuttering (limited evidence), premature ejaculation, and premenstrual syndrome. |
| Marketing Status |
approved; investigational; vet_approved |
| ATC Code |
N06AA04 |
| DrugBank ID |
DB01242
|
| KEGG ID |
D00811
|
| MeSH ID |
D002997
|
| PubChem ID |
68539
|
| TTD Drug ID |
D0ZS8P
|
| NDC Product Code |
72664-214; 0781-2027; 0904-7039; 16714-849; 46708-408; 51407-757; 71205-912; 38779-2256; 71554-024; 16571-685; 16714-851; 46708-407; 52817-282; 59651-381; 60429-287; 0406-9907; 0406-9908; 68084-790; 68084-818; 51927-4511; 27241-210; 59651-382; 59651-383; 0378-3025; 62332-407; 0406-8808; 70756-407; 69575-4013; 42571-344; 60429-289; 0406-8807; 70710-1066; 70756-405; 70756-406; 70771-1012; 70771-1013; 71205-911; 72664-215; 49452-2149; 16714-850; 27241-211; 51407-759; 51672-4012; 52817-280; 52817-281; 63629-1111; 0378-3075; 71205-910; 72664-216; 45562-1742; 60429-288; 0832-0630; 27241-212; 42571-342; 51672-4011; 0406-9906; 70710-1065; 70710-1067; 0781-2037; 0832-0631; 0832-0632; 0904-7038; 67763-113; 16571-683; 46708-409; 51672-4013; 0378-3050; 69315-167; 16571-684; 51407-315; 51407-316; 51407-317; 51407-758; 62332-408; 62332-409; 0406-8806; 69315-165; 69315-166; 70771-1014; 54154-004; 42571-343 |
| UNII |
2LXW0L6GWJ
|
| Synonyms |
Clomipramine | Chlomipramine | Chlorimipramine | Hydiphen | Clomipramine Maleate (1:1) | Clomipramine Monohydrochloride | Monohydrochloride, Clomipramine | Anafranil | Clomipramine Hydrochloride | Hydrochloride, Clomipramine |
